title: Effect of long-acting LHRH analog (Zoladex) on prostate cancer: evaluated by transrectal ultrasonography.
abstract: Transrectal ultrasonography has proved valuable in assessing the effect of primary treatment modalities for prostate carcinoma. This study shows patients who had a significant reduction in primary tumor volume had a significantly better prognosis and had less local symptoms than did the group of patients that did not have a significant reduction (less than 50%) in primary volume secondary to therapy. Patients were treated with either castration or Zoladex and all had Stage D2 cancer of the prostate.
authors.affiliation: Department of Surgery, Ohio State University, Columbus.
authors.forename: J R
authors.initials: JR
authors.lastname: Drago
authors.forename: J A
authors.initials: JA
authors.lastname: Nesbitt
authors.forename: C
authors.initials: C
authors.lastname: Cirulli
mesh_terms: D000368:Aged; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D017273:Goserelin; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014463:Ultrasonography
chemical_list: D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D002064:Buserelin